HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial Agents and Chemotherapy 2013-02, Vol.57 (2), p.1053-1056
Hauptverfasser:	THEYS, K, VERCAUTEREN, J, GROSSMAN, Z, STRUCK, D, VANDAMME, A.-M, ABECASIS, A. B, SNOECK, J, ZAZZI, M, CAMACHO, R. J, TORTI, C, SCHÜLTER, E, CLOTET, B, SÖNNERBORG, A, DE LUCA, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine Adenine - analogs & derivatives Adenine - therapeutic use Adult Anti-HIV Agents Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents Biological and medical sciences Cell culture Drug Resistance, Viral - genetics Drug Therapy, Combination Female Genetic Variation HIV Infections - drug therapy HIV Infections - virology HIV Reverse Transcriptase HIV Reverse Transcriptase - genetics HIV-1 - classification HIV-1 - drug effects HIV-1 - enzymology HIV-1 - genetics Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Male Medical sciences Middle Aged Molecular Sequence Data Organophosphonates Organophosphonates - therapeutic use Pharmacology. Drug treatments Reverse Transcriptase Inhibitors Reverse Transcriptase Inhibitors - pharmacology Reverse Transcriptase Inhibitors - therapeutic use RNA-Directed DNA Polymerase - genetics Tenofovir Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!